Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according to the country’s ...

Pfizer (PFE), and Johnson & Johnson (JNJ) secured spots on China's first innovative drug catalog for private insurance, ...

Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics, as the Chinese biotech tacks on preclinical ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

Triana Biomedicines has tapped Pfizer Ventures and a number of other existing and new investors to secure a $120 million ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

And one of them is pharmaceutical giant Pfizer ( PFE 0.04%). Now, with a major step along the path to entering this ...

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

If you own or are considering buying pharma laggards Pfizer (NYSE: PFE), Bristol Myers Squibb (NYSE: BMY), and Merck (NYSE: ...

Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped ...

PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare ...